Royalty Report: Medical, Diagnostic, Cancer – Collection: 301243

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Diagnostic
  • Cancer
  • bone marrow
  • Tissue
  • Device
  • Technical Know How

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 301243

License Grant
With the amendment, the Licensee obtained license for a certain patent.  

Under the Agreement, each party has an undivided joint ownership interest in all of the patents and other intellectual property rights for such Target-Selector technology,  The license is exclusive, worldwide, irrevocable, and sublicensable.

License Property
The original agreement related to Target-Selector technology.

The patent relates to reagents and kits where the sample types are tissue, whole blood, bone marrow, cerebrospinal fluid or derivatives of any of the foregoing.

Field of Use
The patent relates  vitro diagnostic kits, or IVDs as applied to the oncology field.

The field of use is oncology, all applications in the fields of oncology clinical testing and oncology diagnostics, including both laboratory developed tests and IVD tests as applied to the oncology field, and oncology basic and clinical research.

IPSCIO Record ID: 352725

License Grant
The Parties and others have entered into the Settlement Agreement dated as of the Effective Date.   Both of the Parties desire to continue their current businesses related to the sale of services in the NIPT LDT Field.

The Parties desire for Licensee to have the exclusive right to Exploit the Pooled Patents in the NIPT IVD Field.

Licensee will have
– the exclusive, worldwide, sublicensable right under the Pooled Patents to Exploit NIPT IVD Products in the NIPT IVD Field,
– the exclusive, worldwide, sublicensable right under the Pooled Patents, excluding the Isis Patents, to Exploit NIPT LDT Tests in the NIPT LDT Field, subject to the non-exclusive rights granted to, or reserved by, the Licensor Parties, and
– the nonexclusive, worldwide, sublicensable right under the Isis Patents to Exploit NIPT LDT Tests in the NIPT LDT Field.

Licensor on behalf of itself and its Affiliates, grants to Licensee and its Affiliates an exclusive, irrevocable and perpetual, non-transferable and non-assignable, worldwide license, with the exclusive right to grant sub licenses, under the Licensor Owned Patents and Isis Patents, to Exploit NIPT LDT Tests in the NIPT LDT Field and to Exploit NIPT IVD Products in the NIPT IVD Field, provided that the license is Royalty bearing with respect to NIPT IVD Products and the license is Test Fee-bearing with respect to NIPT LDT Tests.

License Property
Pooled Patents means patents owned or controlled by Licensee and the Licensor.

NIPT IVD Product means a distributable in vitro diagnostic device that has either received applicable Regulatory Approval for sale and use to conduct or perform, in whole or in part, NIPT or is otherwise particularly labeled and marketed for use to conduct or perform NIPT, in whole or in part, excluding general purpose products and components labeled for research use only.

Licensor noninvasive prenatal testing (NIPT) is a chromosome counting method that analyzes genetic information in fetal cell-free DNA in maternal blood to determine risk for specific fetal chromosomal and subchromosomal abnormalities.

Field of Use
Licensed NIPT Field means, collectively, the NIPT IVD Field and NIPT LDT Field.  NIPT means in vitro cell-free nucleic acid-based non-invasive prenatal testing, including, without limitation, testing by massively parallel sequencing or digital PCR, of a biological sample, including but not limited to plasma, serum, whole blood, and urine, obtained from a pregnant woman, excluding oncology testing.

IPSCIO Record ID: 315834

License Grant
For the Licensed Technology, Licensor grants a non-exclusive license under the Licensed Technology to make, have made, use, sell, offer for sale and import Licensed Uses in the Territory in the Field.

For the Research, Licensee shall perform primary testing associated with a validation study of its laboratory -developed test using the Licensed Technology in connection with MD Anderson Cancer Center or an equivalent academic cancer center (with the exception of tissue biopsy) including expression testing, the PSA and send-out of the PCA-3, the Validation Study.  Licensee shall have the right to perform research on remnants after all testing required for the Validation Study is completed, and will be provided reasonable access to the patient data related to the applicable samples.  Licensor shall obtain IRB approval for the study with MD Anderson Cancer Center by February 28, 2009 or, with an equivalent academic institution by June 30, 2009.

For the Purchasing Rights, upon issuance of FDA clearance or approval of an in vitro diagnostic kit using the Licensed Technology (IVD Kit), Licensee shall have the obligation to purchase IVD Kits for reference laboratory use from Licensor’s designated manufacturer or distributor pursuant to a purchasing agreement between Licensee and the applicable manufacturer or distributor, provided however that Licensor shall negotiate to cause such manufacturer or distributor to provide Most Favored Terms to Licensee.

License Property
Licensor has rights in the Licensed Technology covering genomic biomarkers related to prostate cancer.  Licensor is a machine learning company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. The Company operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery.

The patents include
Method of Identifying Patterns in Biological Systems and Uses Thereof;
Biomarkers Overexpressed in Prostate Cancer;
Biomarkers Upregulated in Prostate Cancer; and,
Methods for Screening, Predicting and Monitoring Prostate Cancer.

Field of Use
Field shall mean clinical diagnostic applications using biomarkers in urine for differentiating clinically significant prostate cancer from other prostate conditions, including without limitation clinical laboratory testing and clinical trials, but expressly excluding manufacture of in vitro diagnostic kits.

Licensees focus is developing a test for and performing clinical laboratory diagnostic testing using gene biomarkers detected in patient urine samples for differentiating clinically significant prostate cancer from other prostate conditions.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.